![](/cdn/assets/images/search/clock.png)
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Tyratech (DI) | LSE:TYRU | London | Ordinary Share | COM SHS USD0.001 (DI) |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 3.00 | 2.80 | 3.20 | - | 0.00 | 01:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
0 | 0 | N/A | 0 |
Date | Subject | Author | Discuss |
---|---|---|---|
29/9/2015 09:49 | Well these mm's are consistent, if nothing else. Another £350,000 wiped off the market cap on a £700 sell. Deary me. Some Director buying is required now if this is as good as they make it out to be. | ![]() michaelsadvfn | |
28/9/2015 15:59 | £1.3m wiped off the market cap on a £5k sale. Bottom drawer for these until sentiment changes. Perhaps they should have worded the RNS differently instead of throwing in the 'not as good as expected' bit. After a decent first half, followed by a second half which is expected to be 'materially better than the first half' it seems an odd reaction to the share price. | ![]() michaelsadvfn | |
24/9/2015 08:42 | Since the half year–end, Boots has taken the Vamousse Protective Shampoo into a portion of their stores and expanded the outlets taking the Vamousse Treatment product. NOTE PORTION! NOT ALL why???? Sales have continued to grow in absolute terms during the ‘back to school’ period in August and September to date, however they have been behind our forecast expectations and if this trend continues for the remainder of the year, our second half results, whilst still expected to be materially better than the first half, will not be as strong as previously thought. they are talking sales into shops but how many have actually been sold? they say they are no 3 but what are the actual figures. michael you are the expert please post the figures for no 1 , 2 and 3 so we can compare. to say we are no 3 is meaningless no1 could be $50m no 2 $30m and no 3 $100k. no 4 $30K. | ![]() haroldthegreat | |
24/9/2015 07:51 | Why would they need another placing when they have just stated they foresee sufficient cash for the next 12 months? There will be no placing any time soon. | ![]() michaelsadvfn | |
24/9/2015 07:47 | Decent figures, but below forecasts.... but they need another placing imo | ![]() captain_kurt | |
24/9/2015 07:42 | Earlier than expected, results out. Number 3 OTC head lice brand by dollar sales in the US | ![]() michaelsadvfn | |
21/9/2015 13:53 | Odd share price movement, first tick up on a few buys, second tick up on....? We need volume but we aren't getting it. | ![]() michaelsadvfn | |
18/9/2015 08:59 | Good reviews on Walmart.com site. 10/11 give a 5* rating... | ![]() michaelsadvfn | |
18/9/2015 05:12 | harold, I just checked the Hedrin mousse reviews on Amazon. 4 reviews all gave the product 1 star. It is ranked as the 47th best seller versus 10th for Vamousse. Now what would folk think of Tyratech if Vamousse sat there with 4 out of 4 1 star ratings? I'd be seriously concerned. Worth remembering Vamousse hasn't yet gone through a full head lice season; it will take time to gain traction but all the signs are good so far from what I have seen. | ![]() michaelsadvfn | |
17/9/2015 12:44 | We can easily check the online price and on this occasion you are posting the truth. The rest can't so easily be checked by most so it would be advisable that readers treat the rest of your post with skepticism in light of your previous postings. | ![]() hampton1 | |
17/9/2015 12:01 | it is £10 on line today so either they are delisting in finchley road or the stores are selling it on promotion at a cheaper price and not on line.the full rrp is £15. the product that sells best with customer demand is hedrin in my area. my local sainsbury does not even stock it. | ![]() haroldthegreat | |
17/9/2015 11:43 | That's what we are hoping for. Everything xxd. | ![]() michaelsadvfn | |
17/9/2015 11:32 | Any mass buying triggered by good results would see this fly and the share price would soon be double figures !!!!!! | ![]() hampton1 | |
17/9/2015 11:22 | Another buy and another move up. | ![]() hampton1 | |
17/9/2015 10:37 | Doesn't take much buying to move the price at all. 4 trades, 2 ticks. | ![]() michaelsadvfn | |
17/9/2015 10:33 | I'd be very happy with 15p believe me ! | ![]() michaelsadvfn | |
17/9/2015 10:29 | 15p is still a lot higher than where it sits now. The market for Vamousse is growing as are sales from what I can see as you have been saying. | ![]() hampton1 | |
17/9/2015 10:25 | The big rise in 2014 saw the market cap reach £40m which was far too high at the time. There are more shares in existence now due to the fund raise to get the U.K. up and running. 15p would see that £40m hit again but this time I think such a rise would be justified. Results in 13 days at most. | ![]() michaelsadvfn | |
17/9/2015 10:14 | Could it hit the high of spring 2014 20p plus ! | ![]() hampton1 | |
17/9/2015 10:05 | Up again on steady buying this could go a long way if results live up to expectations. | ![]() hampton1 | |
17/9/2015 07:10 | I had most of my TYR flipped recently, 95k to go. Isn't it nice to be called smart? lol | ![]() michaelsadvfn | |
17/9/2015 07:01 | That was me. I have always bought TYR and flipped some of them to TYRU. Nobby | ![]() nobbygnome | |
16/9/2015 13:15 | Smart money picking up TYR stock as they are cheaper. +10.3% today. | ![]() michaelsadvfn | |
16/9/2015 10:47 | It's just the volume they've got wrong on the treatment. It comes in 160ml, not 200ml bottles. They've got the price per 100ml correct though. £10 per bottle, which is cheaper than on Amazon. Only 1 left in stock with the current retailer there. | ![]() michaelsadvfn |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions